Literature DB >> 873618

Immunoprophylaxis of experimental Mycoplasma pneumoniae disease: effect of route of administration on the immunogenicity and protective effect of inactivated M. pneumoniae vaccine.

H Greenberg, C M Helms, M B Grizzard, W D James, R L Horswood, R M Chanock.   

Abstract

Formalin-inactivated Mycoplasma pneumoniae vaccine was administered subcutaneously or intranasally to hamsters to examine the effect of route of administration on immunogenicity and protective effect. Parenterally administered vaccine in the doses employed induced serum complement-fixing antibody formation, but did not significantly decrease the frequency of pneumonia following challenge with virulent M. pneumoniae. Intranasally instilled vaccine was ineffective in stimulating serum antibody, but did diminish the frequency of experimentally induced pneumonia due to M. pneumoniae. However, a greater degree of resistance was induced by intranasal infection with either wild-type organisms or the ts 640 attenuated mutant of M. pneumoniae.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 873618      PMCID: PMC421492          DOI: 10.1128/iai.16.1.88-92.1977

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  13 in total

1.  Protective Effect of Vaccines in Experimental Mycoplasma pneumoniae Disease.

Authors:  G W Fernald; W A Clyde
Journal:  Infect Immun       Date:  1970-06       Impact factor: 3.441

2.  Immunoprophylaxis of experimental Mycoplasma pneumoniae disease: effect of aerosol particle size and site of deposition of M. pneumoniae on the pattern of respiratory infection, disease, and immunity in hamsters.

Authors:  J V Jemski; C M Hetsko; C M Helms; M B Grizzard; J S Walker; R M Chanock
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

3.  Antibody to Mycoplasma pneumoniae in nasal secretions and sputa of experimentally infected human volunteers.

Authors:  H Brunner; H B Greenberg; W D James; R L Horswood; R B Couch; R M Chanock
Journal:  Infect Immun       Date:  1973-10       Impact factor: 3.441

4.  Asymptomatic infection of adult volunteers with a temperature sensitive mutant of Mycoplasma pneumoniae.

Authors:  H Greenberg; C M Helms; H Brunner; R M Chanock
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

Review 5.  Mycoplasma pneumoniae disease: clinical spectrum, pathophysiology, epidemiology, and control.

Authors:  F W Denny; W A Clyde; W P Glezen
Journal:  J Infect Dis       Date:  1971-01       Impact factor: 5.226

6.  Biologic effects of Mycoplasma pneumoniae and other mycoplasmas from man on hamster tracheal organ culture.

Authors:  A M Collier; W A Clyde; F W Denny
Journal:  Proc Soc Exp Biol Med       Date:  1969-12

7.  Mycoplasma pneumoniae: hydrogen peroxide secretion and its possible role in virulence.

Authors:  G Cohen; N L Somerson
Journal:  Ann N Y Acad Sci       Date:  1967-07-28       Impact factor: 5.691

8.  Epidemiology of M. pneumoniae infection in military recruits.

Authors:  R M Chanock; H H Fox; W D James; R R Gutekunst; R J White; L B Senterfit
Journal:  Ann N Y Acad Sci       Date:  1967-07-28       Impact factor: 5.691

9.  Epidemiological studies of Mycoplasma pneumoniae infections in civilians.

Authors:  J T Grayston; G E Kenny; H M Foy; R A Kronmal; E R Alexander
Journal:  Ann N Y Acad Sci       Date:  1967-07-28       Impact factor: 5.691

10.  Ultrastructural changes in hamster tracheal ring cultures exposed to Mycoplasma pneumoniae.

Authors:  K H Woodruff; E Schneider; L Unger; J J Coalson
Journal:  Am J Pathol       Date:  1973-07       Impact factor: 4.307

View more
  9 in total

Review 1.  Immunity to mycoplasma infections of the respiratory tract: a review.

Authors:  G Taylor
Journal:  J R Soc Med       Date:  1979-07       Impact factor: 5.344

2.  Immunoprophylaxis of experimental Mycoplasma pneumoniae disease: effect of aerosol particle size and site of deposition of M. pneumoniae on the pattern of respiratory infection, disease, and immunity in hamsters.

Authors:  J V Jemski; C M Hetsko; C M Helms; M B Grizzard; J S Walker; R M Chanock
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

3.  Age-related prevalence of complement-fixing antibody to Mycoplasma pneumoniae during an 8-year period.

Authors:  A Pönkä; P Ukkonen
Journal:  J Clin Microbiol       Date:  1983-04       Impact factor: 5.948

4.  Hemadsorption and virulence are separable properties of Mycoplasma pneumoniae.

Authors:  D K Leith; E J Hansen; R M Wilson; D C Krause; J B Baseman
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

5.  Antimycoplasmal activity of ofloxacin (DL-8280).

Authors:  Y Osada; H Ogawa
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

6.  Mucosal nasopharyngeal immune responses of horses to protein antigens of Streptococcus equi.

Authors:  J E Galan; J F Timoney
Journal:  Infect Immun       Date:  1985-03       Impact factor: 3.441

7.  A potassium thiocyanate extract vaccine prepared from Pasteurella multocida 3:A protects rabbits against homologous challenge.

Authors:  Y S Lu; S P Pakes; L Massey; C Stefanu
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

8.  Hamster challenge potency assay for evaluation of Mycoplasma pneumoniae vaccines.

Authors:  M F Barile; D K Chandler; H Yoshida; M W Grabowski; S Razin
Journal:  Infect Immun       Date:  1988-09       Impact factor: 3.441

9.  Class-specific antibody responses to Mycoplasma pulmonis in sera and lungs of infected and vaccinated mice.

Authors:  G Taylor; C J Howard
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.